A reading of the "Lost Gospel of Mary" (Frederica's name for it), from her book of that title. The scholarly name is "the Protevangelion of James" (or "protevangelium" in Latin). It is a timely story for Nativity Fast because it covers the Virgin's life from her conception through the birth of Christ and the slaughter of the innocents.

Frederica discusses the Protevangelion.

In the seventeenth century, the Kingdom of Georgia was cruelly pressed by the Ottoman Empire on one side and Persia, under Shah Abbas the Great, on the other. King Theimuraz was taken captive by the Persians during an invasion and held captive in the fortress of Shiraz until, after many tortures, he was strangled.   The King's mother, Queen Ketevan, travelled to the Persian court at Shiraz along with her grandsons Levan and Alexander, to plead with the Shah to spare the Kingdom. The Shah agreed, but the three were kept as hostages, where all were cruelly tortured.   Queen Ketevan endured ten years of captivity, throughout which the Shah attempted to convert her to Islam, first by persuasion and threats, then by torture. The Queen refused every effort to drive her into apostasy, and before each new torture would make the sign of the Cross and say 'In the Name of the Father and of the Son and of the Holy Spirit.' At the end a brazier of burning coals was fixed to her head and, in the midst of her extreme torment, she was strangled with a bow-string on September 13 1624. After her glorious martyrdom a divine light surrounded her tomb.

The addition expands Tate & Lyle’s ability to help customers solve stevia solubility issues in foods and helps deliver on consumer demand for healthier sugar- and calorie-reduced products.

FourKites has announced that Teva, a global provider of generic medicines, has achieved a 0.005% incident rate by leveraging FourKites’ global carrier visibility solution, NIC-Place.

European Commission fines MS drug maker Teva over improper patent use

Delaware to receive nearly $70 million to fight the opioid crisis Delaware Attorney General Kathy Jennings today announced the final approval of $17.3 billion in opioid agreements with drug makers Teva and Allergan and pharmacies CVS and Walgreens. Following successful state sign-on and subdivision sign-on periods, the defendants have committed to the deal and will start releasing funds […]

Inteva Products’ expansion project to increase the plant’s production space by 70 per cent, to a total of 85,000 square feet

(United States Supreme Court) - Held that an inventor's sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art for purposes of determining the patentability of the invention. The dispute here involved two pharmaceutical companies that disagreed about whether a certain drug was under patent; one of the companies wanted to market a generic version of it. Justice Thomas delivered the unanimous opinion.

(United States Supreme Court) - Held that an inventor's sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art for purposes of determining the patentability of the invention. The dispute here involved two pharmaceutical companies that disagreed about whether a certain drug was under patent; one of the companies wanted to market a generic version of it. Justice Thomas delivered the unanimous opinion.

(United States Supreme Court) - Held that an inventor's sale of an invention to a third party who is obligated to keep the invention confidential can qualify as prior art for purposes of determining the patentability of the invention. The dispute here involved two pharmaceutical companies that disagreed about whether a certain drug was under patent; one of the companies wanted to market a generic version of it. Justice Thomas delivered the unanimous opinion.

A US federal judge has ruled that generic versions of the cancer treatment Bendeka infringe on four separate patents, and has delayed them from launching until 2031.

Israel-based Teva Pharmaceutical Industries today reported results for the quarter ended March 31, 2020,…

With its multibillion-dollar restructuring plan in the rearview mirror, Teva is pinning its future growth on two of its branded meds with high hopes. But generics are still central to the Israeli drugmaker's business, and increased demand due to COVID-19 gave Teva a welcome gift in the first three months of the year.

Teva Pharmaceuticals USA Inc. has agreed to pay a $2.25 million civil penalty to settle alleged violations of the federal Clean Air Act (CAA), Clean Water Act (CWA), and the Resource Conservation and Recovery Act (RCRA), as well as the Missouri Air Conservation Law, Clean Water Law and Hazardous Waste Management Law at its facility in Mexico, Mo.

Kare Schultz, CEO of Teva Pharmaceuticals, joins "Squawk on the Street" to discuss the coronavirus pandemic and potential treatments.

Kare Schultz, CEO of Teva Pharmaceuticals, joins "Squawk on the Street" to discuss the coronavirus pandemic and treatment.

Cham : Springer, [2019]

Hayden Library - PQ2671.R547 D813 2016

Hayden Library - PQ2671.R547 H6713 2017

Online Resource

Like the song? Tell us what you think of it!

Hayden Library - P299.G73 H455 2019

Hayden Library - TP248.65.L54 C4575 2018